A Phase I trial of Neoepitopes immunotherapy for Ovarian cancer
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Neoepitope immunotherapy IMV (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
Most Recent Events
- 29 Jan 2019 New trial record
- 17 Jan 2019 According to an IMV Inc media release, first patient has been dosed in this trial. This trial is being sponsored by the UConn Health (University of Connecticut School of Medicine) under a collaboration agreement with the company. IMV will provide materials and counsel.